Table 3. Administered valproate dose and plasma level of valproate.
| Pat no | Cycle | Valproate dose/kg/day | P-valproate (μM) | |||
|---|---|---|---|---|---|---|
| Day 1 | Day 2 | Day 3 | Day 4 | |||
| 01 | 1 | 60 | < 20 | 1108 | 1505* | 611 |
| 2 | 60 | < 20 | 1046 | 1568* | 502 | |
| 3 | 30 | < 20 | 605 | 796 | 889 | |
| 02 | 1 | 60 | < 20 | 1198 | 781 | 826 |
| 2 | 60 | < 20 | 669 | 798 | 985 | |
| 3 | 60 | < 20 | 461 | 833 | Not done | |
| 04 | 1 | 60 | < 20 | 685 | 932 | 1123 |
| 2 | 60 | < 20 | 908 | 1288* | 638 | |
| 3 | 30 | < 20 | 638 | 852 | 833 | |
Patients were administered oral valproate divided on three doses per day, starting after blood sampling morning day 1. Last dose was given evening day 3. Cycle length was 21 days. All sampling was performed in the morning. *Day 3 doses 2 and 3 were excluded during due to fatigue and dizziness.